Report on community-acquired pneumonia: Review of the 4th Consensus Conference on anti-infectious therapy of the Société de Pathologie Infectieuse de Langue Française (SPILF);Argumentaire pneumonie communautaire: Révision de la IVe Conférence de consensus en thérapeutique anti-infectieuse de la Société de Pathologie Infectieuse de Langue Française (SPILF)

Medecine et Maladies Infectieuses

Volumn 31, Issue 5, 2001, Pages 268-301

  Chidiac, C ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; COTRIMOXAZOLE; ERYTHROMYCIN; LORACARBEF; PENICILLIN G; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; DISEASE TRANSMISSION; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; PNEUMONIA; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY;

EID: 18344399273     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(01)00203-7     Document Type: Conference Paper

References (209)

1. Infections respiratoires basses de l'adulte: Pneumonie communautaire et bronchite aiguë
2. Management of adult community-acquired lower respiratory tract infections
3. Community-acquired pneumonia in adults: Guidelines for management
4. Community-acquired pneumonia. Importance of initial non invasive bacteriologic and radiographic investigation
5. Nursing home acquired pneumonia. A case control study
6. Epidémiologie de la flore nasopharyngée au cours des otites moyennes aiguës de l'enfant en 1997
7. Données épidémiologiques de la résistance aux antibiotiques des Haemophilus, méningocoques, Listeria
8. Isolation and molecular characterization of a ROB-1 beta-lactamase plasmid in a Haemophilus influenzae strain in France
9. Canadian Haemophilus study group, Low DE, Determination of antimicrobial susceptibilities of canadian isolates of Haemophilus influenzae and characterization of their β-lactamases
10. Penicillin-binding proteins and ampicillin resistance in Haemophilus influenzae
11. Targets of the beta-lactam antibiotics penicillin-binding proteins in ampicillin-resistant, non-lactamase-producing Haemophilus influenzae
12. In vitro activity of cefpodoxime against pathogens responsible for community-acquired respiratory tract infections
13. In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae
14. Activité du Centre National de Référence des Haemophilus influenzae, années 1996-1997: Le déclin du type b
15. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine
16. Effect of cefotaxime or ceftriaxone treatment on nasopharyngeal Haemophilus influenzae type b colonization in children
17. Pneumococcal resistance to antibiotics
18. Impact of antibiotic resistance on chemotherapy for pneumococcal infections
19. Activity of penicillin and three third-generation cephalosporins against US isolates of Streptococcus pneumoniae: A 1995 surveillance study
20. Epidémiologie bactérienne des otites moyennes aiguës de l'enfant en France en 1993
21. Flore rhinopharyngée et résistance du pneumocoque
22. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci
23. Effects of cefixime or coamoxicalulanic treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media
24. Low dosage and long treatment duration of β-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae
25. The spread of multiply resistant Streptococcus pneumoniae at a Day Care Center in Ohio
26. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: Findings of a French Survey
27. Pathogens isolated during treatment failures in otitis
28. Penicillin-resistant Streptococcus pneumoniae strains recovered in Houston: Identification and molecular characterization of multiple clones
29. Genetic relationships of penicillin-susceptible and -resistant Streptococcus pneumoniae strains isolated on different continents
30. Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae
31. Multiply antibiotic-resistant Streptococcus pneumoniae recovered from Spanish hospitals (1988-1994): Novel major clones of serotypes 14, 19F and 15F
32. Genetic relationship of penicillin resistant Streptococcus pneumoniae serotype 19B strains in Japan
33. Clonal distribution of penicillin-resistant Streptococcus pneumoniae 23F in France
34. Epidémiologie moléculaire de la résistance des pneumocoques à la pénicilline
35. Spread of the serotype 23F multidrug-resistant Streptococcus pneumoniae clone to South Korea
36. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s
37. Relatedness of penicillin-resistant Streptococcus pneumoniae serogroup 9 strains from France and Spain
38. Genetic relatedness within and between serotypes of Streptococcus pneumoniae from the United Kingdom: Analysis of multilocus enzyme electrophoresis, pulsed-field gel electrophoresis, and antimicrobial resistance patterns
39. Pulsed field gel electrophoresis in Streptococcus pneumoniae isolated in France and Portugal
40. Penicillin-resistant Streptococcus pneumoniae in Germany: Genetic relationship to clones from other European countries
41. Molecular epidemiology of penicillin-resistant pneumococci isolated in Nairobi, Kenya
42. Relatedness of penicillin-binding protein la genes from different clones of penicillin-resistant Streptococcus pneumoniae isolated in South Africa and Spain
43. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: Evidence suggesting capsular transformation of the resistant strain in vivo
44. Mechanisms of the spread of penicillin resistance in Streptococcus pneumoniae strains causing meningitis in children in France
45. In-vitro activities of 16 non-β-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae
46. The Spanish Surveillance Group for Respiratory Pathogens, Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study
47. Drug-resistant Streptococcus pneumoniae
48. Expérience clinique du traitement par l'amoxicilline des pneumonies à pneumocoque de sensibilité diminuée à la pénicilline G
49. Clinical implications of penicillin and ceftriaxone resistance among children with pneumococcal bacteremia
50. Management of infections due to antibiotic-resistant Streptococcus pneumoniae
51. Serum protein binding and extravascular diffusion of methoxyimino cephalosporins time courses of free and total concentrations of cefotaxime and ceftriaxone in serum and pleural exudate
52. Haemophilus influenzae (CNR)
53. Prevalence of antimicrobial resistance in respiratory tract isolates of S. pneumoniae: Results of a canadian national surveillance study
54. Economic costs of respiratory tract infections in the United states
55. New and emerging etiologies for community-acquired pneumonia with implications for therapy
56. The characteristics and mortality of outpatient-acquired pneumonia
57. Adult pneumonia in a General Hospital. Etiology and Host risk factors
58. Risk factors for acquiring pneumococcal infections
59. Risk factors pneumonia in the elderly
60. Community-acquired pneumonia factors influencing intensive care admission
61. Hospitalization decision in patients with community-acquired pneumonia: A prospective cohort study
62. Assessing prognosis and predicting patient outcomes in community acquired pneumonia
63. Community-acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors and outcome
64. Predicting death in patients hospitalized for community acquired pneumonia
65. Community-acquired pneumonia: Aetiology and prognostic index evaluation
66. Community acquired pneumonia: Aetiology and usefulness of severity criteria on admission
67. Assessment of severity of community-acquired pneumonia
68. Prognosis of patients hospitalized with community-acquired pneumonia
69. A prediction rule to identify low-risk patient with community acquired pneumonia
70. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
71. Antibiothérapie par voie générale en pratique courante : Infections ORL et respiratoires basses
72. The definition of acute respiratory illnesses in general practice
73. A new look at respiratory illness in general practice
74. Pneumonia-a clinical or radiographic diagnosis?
75. Clinical criteria for the detection of pneumonia in adults: Guidelines for ordering chest roentgenograms in the emergency department
76. Decision rules and clinical prediction of pneumonia: Evaluation of low-yield criteria
77. Prediction of pneumonia in outpatients with acute cough
78. Clinical prediction rule for pulmonary infiltrates
79. Use of investigations in lower respiratory tract infection in the community: A European Survey
80. Prospective study of the aetiology and outcome of pneumonia in the community
81. Adulte lower respiratory tract infections: Which investigations are useful to GPs?
82. Prospective study of etiology and outcom of adult lower-respiratory tract-infections in the community
83. Reliability of eliciting physical signs in examination of the chest
84. Diagnosing pneumonia by physical examination. Relevant or Relic?
85. Does this patient have a community-acquired pneumonia?
86. Interobserver variability in the interpretation of chest Roentgenograms of patients with possible pneumonia
87. Interobserver reliabilty of the chest radiograph in community-acquired pneumonia
88. High-resolution computed tomography for the diagnosis of community-acquired pneumonia
89. Interobserver variability in the radiographic diagnosis of adult outpatient pneumonia
90. Radiographic findings in patients with community-acquired pneumonia
91. Detection of pneumonia by auscultation of the lungs in the lateral decubitus positions
92. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia?
93. Prognosis and outcome of patients with community-acquired pneumonia
94. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia
95. Community-acquired pneumonia requiring hospitalization: 5-year prospective study
96. Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs
97. The hospital admission decision for patients with community-acquired pneumonia
98. Severe community-acquired pneumonia
99. Comparative features of Pneumococcal, Mycoplasmal and Legionnaires' disease pneumonia
100. Differential diagnosis of viral, mycoplasmal and bacteraemic pneumococcal pneumonias on admission to hospital
101. Pneumonia due to legionella pneumophila and pneumococcal pneumonia: Similarities and differences in presentation
102. Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonia
103. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features
104. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: A comparison between chlamydial and pneumococcal pneumonia
105. ème Conférence de consensus en thérapeutique anti-infectieuse de la Société de Pathologic Infectieuse de Langue Française. Les infections des voles respiratoires
106. Evaluation of new anti-infective drugs for the treatment of respiratory tract infection
107. Clinical trials of antibacterial agents: A practical guide to design and analysis
108. Aetiology of community-acquired pneumonia in out patients
109. Community-acquired pneumonia: Importance of initial noninvasive bacteriologic and radiographic investigations
110. A prospective hospital study of the aetiology of community-acquired pneumonia
111. Aetiology of community-acquired pneumonia
112. The epidemiology of community-acquired pneumonia among hospitalized adults
113. A comparative study of meropenem and ceftazidime in the treatment of patients hospitalized with community-acquired pneumonia
114. A randomized trial of cefepime and ceftazidime for the treatment of community-acquired pneumonia
115. The efficacy and safety of isepamicin and ceftazidime compared with amikacin and ceftazidime in lower respiratory tract infection
116. Comparison of cefdinir and cefaclor in the treatment of community-acquired pneumonia
117. Intravenous fleroxacin versus ceftazidime for lower respiratory tract and skin and soft-tissue infections
118. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia
119. Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-acid clavulanic and erythromycin
120. Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: A randomized, double-masked, comparative, multicenter study
121. Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia
122. Single daily dose of cefodizime in patients with community-acquired pneumonia
123. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia
124. Randomized, multicentric study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mulit to moderate community-acquired pneumonia
125. Efficacy of a three day course of azithromycin in moderatedly severe community-acquired pneumonia
126. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infection
127. A single-blind comparison of three-day azithromycin and ten-day coamoxiclav treatment of acute lower respiratory tract infection
128. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid in the treatment of adults with lower respiratory tract infections and effects on long term outcom
129. Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infection
130. Clinical efficacy of azithromycin in lower respiratory tract infections
131. A comparative study of dirithromycin and erythromycin in bacterial pneumonia
132. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia
133. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia
134. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia
135. Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia
136. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults
137. Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia
138. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin
139. Treatment of community-acquired pneumonia in the elderly: The rôle of cefepime, a fourth-generation cephalosporin
140. A prospectived randomized study of in patients IV antibodies for community-acquired pneumonia. The optimal duration of therapy
141. Early transition to oral antibiotic for community-acquired pneumonia: Duration of therapy, clinical outcomes and cost analysis
142. Oral versus intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: Open, randomized controlled trial
143. Pharmacoeconomic evaluation of roxithromycine versus amoxycillin/clavulanic acid in a community-acquired lower respiratory tract infection study
144. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients
145. Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany
146. Development of new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics
147. In vitro development of resistance to five quinolones and amoxycillin-clavulanate in Streptococcus pneumoniae
148. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
149. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolons in Canada
150. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials
151. Bacterial polysaccharide vaccines
152. Six newly recognized types of Streptococcus pneumoniae
153. A new 23 valent pneumococcal vaccine: Immunogénicity and reactogenicity in adults
154. Pneumococcal antibody levels. One decade after immunization of healthy adults
155. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides
156. Le pneumocoque. Immunité naturelle et vaccinale en France
157. Anti-pneumococcal antibody response in normal subjects: A meta-analysis
158. Pneumococcal vaccine
159. Antibody to capsular polysaccharide of Streptococcus pneumoniae, prevalence, persistance and response to revaccination
160. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons
161. Immune response of elderly adults to pneumococcus: Variation by age, sex and functionnal impairment
162. Persistance of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly
163. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine
164. Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease
165. Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients
166. Pneumococcal bacteremia with especial reference to bacteremia pneumococcal pneumonia
167. Protective efficacy of pneumococcal polysaccharide vaccines
168. Immunization with a polyvalent pneumococcal vaccine
169. Pneumococcal vaccine: Clinical efficacy and effectiveness
170. Essai clinique du vaccin anti-pneumococcique chez des personnes âgées vivant en institution
171. The pneumococcal vaccine after 15 years of use
172. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study
173. Pneumococcal vaccination in the prevention of community-acquired pneumonia: An optimistic view of cost-effectiveness
174. Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma
175. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease: A pilot study
176. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease
177. Clinical efficacy of pneumococcal vaccine in the elderly: A randomized single-blind population-based trial
178. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people
179. The clinical effectiveness of pneumococcal vaccination: A brief review
180. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections
181. Inefficacy of pneumococcal vaccine in a high-risk population
182. The clinical effectiveness of pneumococcal vaccine in the elderly
183. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
184. Epidemiology of invasive pneumococcal disease
185. Preventing pneumococcal bacteremia in patients at risk. Results of a matched care-control study
186. Pneumococcal disease after pneumococcal vaccination. An alternative method to estimate the efficacy of pneumococcal vaccine
187. Pneumococcal vaccine efficacy in selected population in the United States
188. Pneumococcal polysaccharide vaccine efficacy. An evolution of current recommandations
189. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older
190. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease
191. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease
192. Center for Disease control and prevention of pneumococcal disease. Recommandations of the Advisory Committee on Immunization Practices (ACIP)
193. Side effects associated with pneumococcal vaccination
194. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered in the elderly
195. Safety of revaccination with pneumococcal polysaccharide vaccine
196. The cost effectiveness of pneumococcal vaccination strategie
197. Cost-effectiveness of pneumococcal vaccine: Implications for managed care
198. A cost-benefit analysis of immunization for pneumococcal pneumonia
199. Cost-effecitiveness of neumococcinal vaccination in Catalonia
200. Cost-effectiveness of vaccination against pneumococcal pneumonia in the Netherlands
201. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people
202. Cost-effectiveness of vaccination against pneumocccal pneumonia
203. Evaluation socio-économique d'un vaccin contre l'infection pneumococcique
204. Avis du Conseil Supérieur d'Hygiène Publique en France (Section des maladies transmissibles)